| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
CF53 targets BET bromodomain proteins (BRD2, BRD3, BRD4, and BRDT), which are epigenetic readers that recognize acetylated lysine residues on histones and regulate gene transcription. By binding to the bromodomains of BET proteins, CF53 disrupts their interaction with acetylated histones, leading to inhibition of BET-dependent gene transcription. This has therapeutic implications in cancer and inflammatory diseases.
|
|---|---|
| ln Vitro |
CF53 (compound 28) exhibits significant affinity for the BD1 and BD2 domains of BRD2, BRD3, BRD4, and BRDT BET proteins. Kds for these domains are 0.49, 0.6, and 0.52 nM, respectively, for BRD2 BD1, BRD2 BD2, and BRD3 BD1. 47 nM (CREBBP), 570 nM (CECR2), 110 nM (EP300), 2 nM (BRDT BD1), 2.1 nM (BRDT BD2), 0.8 nM (BRD4 BD2), and nM (BRD3 BD2)[1]. The MOLM-13 acute leukemia and MDA-MB-231 breast cancer cell lines have IC50 values of 7 and 85 nM, respectively, for CF53[1].
In vitro, CF53 demonstrates potent binding to BRD4 BD1 with Ki <1 nM, Kd = 2.2 nM, and IC50 = 2 nM. It shows high affinity for both BD1 and BD2 domains of BET proteins. The compound exhibits potent anti-tumor activity in vitro. Detailed in vitro characterization including IC50 values and selectivity profile are available from published studies. |
| ln Vivo |
CF53 (25, 50 mg/kg, orally) has strong anticancer efficacy in the mouse RS4;11 model and the MDA-MB-231 xenograft tumor model [1].
In vivo, CF53 demonstrates potent anti-tumor activity in animal models. It is orally bioavailable with an oral bioavailability of 71.3% in mice. The compound has been studied in preclinical models for its efficacy in cancer and inflammatory diseases. Specific in vivo data including dose-response relationships and efficacy in tumor models are available from published studies. |
| Enzyme Assay |
In vitro binding assays for BET inhibitors typically use surface plasmon resonance (SPR) or fluorescence polarization (FP) to measure binding affinity to BET bromodomains. Recombinant BRD4 BD1 or BD2 proteins are incubated with varying concentrations of CF53, and binding affinity (Kd) is calculated from binding curves. Competition assays with labeled BET ligands may also be used.
|
| Cell Assay |
In vitro cellular assays for BET inhibitors typically use cancer cell lines. Cells are treated with CF53 at various concentrations, and cell proliferation is measured by MTT or CCK-8 assays. BET target gene expression (e.g., MYC, BCL2) is assessed by qRT-PCR. BRD4 occupancy at target gene promoters is measured by ChIP-qPCR. Apoptosis is assessed by Annexin V/PI staining.
|
| Animal Protocol |
In vivo animal studies for BET inhibitors typically use xenograft tumor models in immunocompromised mice. Animals are administered CF53 orally at various doses. Tumor growth is monitored by caliper measurement. BET target gene expression and pathway modulation are assessed in tumor tissue by qRT-PCR, Western blotting, or immunohistochemistry.
|
| ADME/Pharmacokinetics |
CF53 is orally bioavailable with an oral bioavailability of 71.3% in mice. It has a molecular weight of 443.50 and is soluble in DMSO. The compound is metabolized in the liver, and its metabolites are excreted via the kidneys and bile. Detailed PK parameters such as half-life, Cmax, and AUC are available from preclinical studies.
|
| Toxicity/Toxicokinetics |
Preclinical toxicity studies of CF53 would typically include acute and repeated-dose toxicity in rodents, as well as genotoxicity and safety pharmacology assessments. As a BET inhibitor, potential on-target effects on hematopoiesis and thrombocytopenia should be monitored. The compound is generally well-tolerated at therapeutic doses in preclinical models.
|
| References | |
| Additional Infomation |
CF53 free base is a highly potent, selective, and orally active BET inhibitor with Ki <1 nM, Kd = 2.2 nM, and IC50 = 2 nM for BRD4 BD1. It targets BRD2, BRD3, BRD4, and BRDT BET proteins. The compound demonstrates potent anti-tumor activity in vitro and in vivo and has an oral bioavailability of 71.3% in mice. It is available for research use only.
|
| Molecular Formula |
C24H25N7O2
|
|---|---|
| Molecular Weight |
443.501003980637
|
| Exact Mass |
443.206
|
| CAS # |
1808160-52-2
|
| Related CAS # |
1808160-52-2;1808162-97-1 (TFA);
|
| PubChem CID |
118340554
|
| Appearance |
Light yellow to yellow solid powder
|
| LogP |
4.3
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
33
|
| Complexity |
710
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O(C)C1C(C2C(C)=NOC=2C)=CC2=C(C=1)C1C(=NC(C)=NC=1NC1=CC(C3CC3)=NN1C)N2
|
| InChi Key |
JIYPVUCBRQNICX-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C24H25N7O2/c1-11-21(12(2)33-30-11)16-8-18-15(9-19(16)32-5)22-23(27-18)25-13(3)26-24(22)28-20-10-17(14-6-7-14)29-31(20)4/h8-10,14H,6-7H2,1-5H3,(H2,25,26,27,28)
|
| Chemical Name |
N-(5-cyclopropyl-2-methylpyrazol-3-yl)-7-(3,5-dimethyl-1,2-oxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~110 mg/mL (~248.03 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.83 mg/mL (4.13 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 18.3 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.83 mg/mL (4.13 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 18.3 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2548 mL | 11.2740 mL | 22.5479 mL | |
| 5 mM | 0.4510 mL | 2.2548 mL | 4.5096 mL | |
| 10 mM | 0.2255 mL | 1.1274 mL | 2.2548 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
